Wells Fargo analyst Brandon Couillard downgraded Waters to Equal Weight from Overweight with a price target of $330, down from $420. The firm says that Waters’ (WAT) acquisition of Becton Dickinson’s (BDX) Biosciences & Dx assets has sound strategic merit, but given the deal size, Wells thinks concerns on execution risk could keep shares range-bound and cap its relative valuation premium.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Cautious Hold Rating Amid Waters and Becton Dickinson Merger: Balancing Opportunities and Execution Risks
- Waters Announces Reverse Morris Trust Agreement
- Waters falls -11.7%
- Trump slaps 30% tariffs on EU and Mexico, announces Russia tariffs: Morning Buzz
- Cautious Optimism: Waters’ Transformative $17.5 Billion Merger with Becton, Dickinson’s Bioscience/Dx Business